Skip to main content

Table 1 Laboratory Data

From: Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma

Variable (normal range)1.5 months prior to admissionAt the time of hospital admission2.5 months following admission
Hematocrit (%) (35.7–46.7)4130.138.3
Hemoglobin (g/dl) (12.1–16.3)13.29.812.3
White Cell Count (*109/L) (4–11.1)6.97.58.4
Differential (%)
 Neutrophils74.980.585.6
 Band forms00.60.6
 Lymphocytes13.76.77.0
 Monocytes9.19.95.6
Mean Corpuscular volume (fL) (80–100)91.187.597
Erythrocyte count (*1012/L) (4.18–5.64)4.53.443.95
Potassium (mmol/L) (3.5–5.1)4.44.14.5
Sodium (mmol/L) (133–145)137136135
Chloride (mmol/L) (98–108)103107103
Blood Urea Nitrogen (mg/dl) (7–25)162232
Creatinine (mg/dl) (0.6–1.2)0.981.471.86
Calcium (mg/dl) (8.6–10.3)9.28.69.2
Glucose (mg/dl) (70–199)99162124
Alkaline Phosphatase (U/L) (39–117)1149664
Alanine Aminotransferase (U/L) (7–52)121319
Aspartate Aminotransferase (U/L) (12–39)301719
Bilirubin total (mg/dl) (0.1–1.3)0.70.60.7
Total protein (g/dl) (6.4–8.9)7.16.66.4
Albumin (g/dl) (3.5–5.7)3.62.93.8
ESR (mm/hr) (0–20) 7512
Anti DNA Ab Negative 
Anti Centromere Ab Negative 
Anti RNP Ab Negative 
Anti Smith Ab Negative 
Anti SSA Ab Negative 
Anti SSB Ab Negative 
ANA > 1:320, speckled 
Anti MPO Ab (0–20 units) > 30> 30
C-ANCA NegativeNegative
P-ANCA 1:6401:80
C3 omplement (mg/dl) (87–200) 110 
C4 Complement (mg/dl) (19–52) 25.1